NEOG NEOGEN CORP
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 711377 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.3%
TTM net income YoY94.6%
TTM EPS YoY94.6%
Revenue 3-yr CAGR-1.3%
Net income 3-yr CAGR—
Margins
Gross margin47.4%
Operating margin-0.8%
Net margin-6.3%
FCF margin5.6%
EBITDA margin12.3%
Returns
ROE-2.7%
ROA-1.7%
ROIC (approx.)-0.2%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets36.8%
Debt / equity0.74x
Current ratio3.90x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.52x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 |
|---|---|---|
| Income statement | ||
| Revenue | $870.40M | $894.66M |
| Cost of revenue | $461.90M | $473.30M |
| Gross profit | $408.50M | $421.40M |
| R&D expense | $18.40M | $21.10M |
| SG&A expense | $245.10M | $218.20M |
| Operating income | -$21.60M | -$1.06B |
| Interest expense | $24.10M | $38.10M |
| Pretax income | -$9.00M | -$1.13B |
| Income tax | -$1.10M | -$41.10M |
| Net income | -$7.90M | -$1.09B |
| EBITDA | $94.70M | -$941.50M |
| EPS (basic) | -0.04 | -5.03 |
| EPS (diluted) | -0.04 | -5.03 |
| Weighted avg. shares (diluted) | 217.50M | 216.90M |
| Balance sheet | ||
| Cash & equivalents | $185.50M | $129.00M |
| Short-term investments | — | $0 |
| Receivables | $146.80M | $153.40M |
| Inventory | $144.30M | $190.80M |
| Current assets | $604.60M | $576.90M |
| PP&E, net | $329.80M | $339.10M |
| Goodwill | $1.05B | $1.06B |
| Intangibles | $1.32B | $1.41B |
| Total assets | $3.35B | $3.44B |
| Current liabilities | $158.20M | $174.00M |
| Short-term debt | $800.00M | $19.30M |
| Long-term debt | $793.70M | $874.80M |
| Total debt | $1.59B | $894.10M |
| Total liabilities | $1.25B | $1.37B |
| Shareholders' equity | $2.09B | $2.07B |
| Net debt | $1.41B | $765.10M |
| Shares outstanding | 217.70M | 217.00M |
| Cash flow statement | ||
| Operating cash flow | $83.20M | $58.20M |
| Capital expenditure | $51.30M | $104.60M |
| Free cash flow | $31.90M | -$46.40M |
| Investing cash flow | $70.50M | -$99.20M |
| Financing cash flow | -$99.40M | -$1.60M |
| Depreciation & amortization | $116.30M | $119.50M |
| Stock-based compensation | $13.40M | $17.30M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.